Article

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody Therapy

2021-09-15

Abstract excerpt

<h4>ABSTRACT</h4> Resistance mutations to monoclonal antibody (mAb) therapy has been reported, but in the non-immunosuppressed population, it is unclear if in vivo emergence of SARS-CoV-2 resistance mutations alters either viral replication dynamics or therapeutic efficacy. In ACTIV-2/A5401, non-hospitalized participants with symptomatic SARS-CoV-2 infection were randomized to bamlanivimab (700mg or 7000mg) or pla...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 294f8250-9cc3-5645-9531-0013f2c54a95
DOI: 10.1101/2021.09.03.21263105

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Emergence of SARS-CoV-2 Resistance with Monoclonal Antibody TherapyDOI 10.1101/2021.09.03.21263105Read

Emergence of SARS-CoV-2 escape mutations during Bamlanivimab therapy in a phase II randomized clinical trial.Semantic proximity Read

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatmentSemantic proximity Read

Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.Semantic proximity Read

Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that emerge after treatment.Semantic proximity Read

Complex intra-host SARS-CoV-2 evolution following monoclonal antibody pre-exposure prophylaxisSemantic proximity Read

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in GermanySemantic proximity Read

Acquisition and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patientSemantic proximity Read

Host immunological responses facilitate development of SARS-CoV-2 mutations in patients receiving monoclonal antibody treatments.Semantic proximity Read

SARS-CoV-2 evolution and evasion from multiple antibody treatments in a cancer patientSemantic proximity Read

Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individualSemantic proximity Read

Modeling the emergence of viral resistance for SARS-CoV-2 during treatment with an anti-spike monoclonal antibodySemantic proximity Read

Overcoming Variants Resistance in Monoclonal Antibody for Antiviral TherapySemantic proximity Read